Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, John P. Ray, Carl G. de Boer, Russell W. Jenkins, David J. Lieb, Jonathan H. Chen, Dennie T. Frederick, Michal Barzily-Rokni, Samuel S. Freeman, Alexandre Reuben, Paul J. Hoover, Alexandra Chloé Villani, Elena Ivanova, Andrew Portell, Patrick H. Lizotte, Amir R. Aref, Jean Pierre Eliane, Marc R. HammondHans Vitzthum, Shauna M. Blackmon, Bo Li, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, Zachary A. Cooper, Cloud P. Paweletz, David A. Barbie, Anat Stemmer-Rachamimov, Keith T. Flaherty, Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Nir Hacohen

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors. Two distinct states of CD8+ T cells were defined by clustering and associated with patient tumor regression or progression. A single transcription factor, TCF7, was visualized within CD8+ T cells in fixed tumor samples and predicted positive clinical outcome in an independent cohort of checkpoint-treated patients. We delineated the epigenetic landscape and clonality of these T cell states and demonstrated enhanced antitumor immunity by targeting novel combinations of factors in exhausted cells. Our study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy. Single-cell analysis of immune cells from melanoma patients treated with immune checkpoint therapy uncovers a TCF7+ memory-like state in the cytotoxic T cell population and demonstrates its association with a positive outcome.

Original languageEnglish (US)
Pages (from-to)998-1013.e20
JournalCell
Volume175
Issue number4
DOIs
StatePublished - Nov 1 2018
Externally publishedYes

Fingerprint

T-cells
Immunotherapy
Tumors
Melanoma
T-Lymphocytes
Neoplasms
Transcriptome
Single-Cell Analysis
Therapeutics
Transcription Factors
Epigenomics
Cluster Analysis
Immunity
Data storage equipment
Population

Keywords

  • cancer immunotherapy
  • CD8 T cells
  • checkpoint blockade
  • single-cell RNA-seq
  • TCF7

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., ... Hacohen, N. (2018). Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 175(4), 998-1013.e20. https://doi.org/10.1016/j.cell.2018.10.038

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. / Sade-Feldman, Moshe; Yizhak, Keren; Bjorgaard, Stacey L.; Ray, John P.; de Boer, Carl G.; Jenkins, Russell W.; Lieb, David J.; Chen, Jonathan H.; Frederick, Dennie T.; Barzily-Rokni, Michal; Freeman, Samuel S.; Reuben, Alexandre; Hoover, Paul J.; Villani, Alexandra Chloé; Ivanova, Elena; Portell, Andrew; Lizotte, Patrick H.; Aref, Amir R.; Eliane, Jean Pierre; Hammond, Marc R.; Vitzthum, Hans; Blackmon, Shauna M.; Li, Bo; Gopalakrishnan, Vancheswaran; Reddy, Sangeetha M.; Cooper, Zachary A.; Paweletz, Cloud P.; Barbie, David A.; Stemmer-Rachamimov, Anat; Flaherty, Keith T.; Wargo, Jennifer A.; Boland, Genevieve M.; Sullivan, Ryan J.; Getz, Gad; Hacohen, Nir.

In: Cell, Vol. 175, No. 4, 01.11.2018, p. 998-1013.e20.

Research output: Contribution to journalArticle

Sade-Feldman, M, Yizhak, K, Bjorgaard, SL, Ray, JP, de Boer, CG, Jenkins, RW, Lieb, DJ, Chen, JH, Frederick, DT, Barzily-Rokni, M, Freeman, SS, Reuben, A, Hoover, PJ, Villani, AC, Ivanova, E, Portell, A, Lizotte, PH, Aref, AR, Eliane, JP, Hammond, MR, Vitzthum, H, Blackmon, SM, Li, B, Gopalakrishnan, V, Reddy, SM, Cooper, ZA, Paweletz, CP, Barbie, DA, Stemmer-Rachamimov, A, Flaherty, KT, Wargo, JA, Boland, GM, Sullivan, RJ, Getz, G & Hacohen, N 2018, 'Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma', Cell, vol. 175, no. 4, pp. 998-1013.e20. https://doi.org/10.1016/j.cell.2018.10.038
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 Nov 1;175(4):998-1013.e20. https://doi.org/10.1016/j.cell.2018.10.038
Sade-Feldman, Moshe ; Yizhak, Keren ; Bjorgaard, Stacey L. ; Ray, John P. ; de Boer, Carl G. ; Jenkins, Russell W. ; Lieb, David J. ; Chen, Jonathan H. ; Frederick, Dennie T. ; Barzily-Rokni, Michal ; Freeman, Samuel S. ; Reuben, Alexandre ; Hoover, Paul J. ; Villani, Alexandra Chloé ; Ivanova, Elena ; Portell, Andrew ; Lizotte, Patrick H. ; Aref, Amir R. ; Eliane, Jean Pierre ; Hammond, Marc R. ; Vitzthum, Hans ; Blackmon, Shauna M. ; Li, Bo ; Gopalakrishnan, Vancheswaran ; Reddy, Sangeetha M. ; Cooper, Zachary A. ; Paweletz, Cloud P. ; Barbie, David A. ; Stemmer-Rachamimov, Anat ; Flaherty, Keith T. ; Wargo, Jennifer A. ; Boland, Genevieve M. ; Sullivan, Ryan J. ; Getz, Gad ; Hacohen, Nir. / Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. In: Cell. 2018 ; Vol. 175, No. 4. pp. 998-1013.e20.
@article{be0ab5d2b19b40b3977150e9a44f9aa6,
title = "Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma",
abstract = "Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors. Two distinct states of CD8+ T cells were defined by clustering and associated with patient tumor regression or progression. A single transcription factor, TCF7, was visualized within CD8+ T cells in fixed tumor samples and predicted positive clinical outcome in an independent cohort of checkpoint-treated patients. We delineated the epigenetic landscape and clonality of these T cell states and demonstrated enhanced antitumor immunity by targeting novel combinations of factors in exhausted cells. Our study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy. Single-cell analysis of immune cells from melanoma patients treated with immune checkpoint therapy uncovers a TCF7+ memory-like state in the cytotoxic T cell population and demonstrates its association with a positive outcome.",
keywords = "cancer immunotherapy, CD8 T cells, checkpoint blockade, single-cell RNA-seq, TCF7",
author = "Moshe Sade-Feldman and Keren Yizhak and Bjorgaard, {Stacey L.} and Ray, {John P.} and {de Boer}, {Carl G.} and Jenkins, {Russell W.} and Lieb, {David J.} and Chen, {Jonathan H.} and Frederick, {Dennie T.} and Michal Barzily-Rokni and Freeman, {Samuel S.} and Alexandre Reuben and Hoover, {Paul J.} and Villani, {Alexandra Chlo{\'e}} and Elena Ivanova and Andrew Portell and Lizotte, {Patrick H.} and Aref, {Amir R.} and Eliane, {Jean Pierre} and Hammond, {Marc R.} and Hans Vitzthum and Blackmon, {Shauna M.} and Bo Li and Vancheswaran Gopalakrishnan and Reddy, {Sangeetha M.} and Cooper, {Zachary A.} and Paweletz, {Cloud P.} and Barbie, {David A.} and Anat Stemmer-Rachamimov and Flaherty, {Keith T.} and Wargo, {Jennifer A.} and Boland, {Genevieve M.} and Sullivan, {Ryan J.} and Gad Getz and Nir Hacohen",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.cell.2018.10.038",
language = "English (US)",
volume = "175",
pages = "998--1013.e20",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

AU - Sade-Feldman, Moshe

AU - Yizhak, Keren

AU - Bjorgaard, Stacey L.

AU - Ray, John P.

AU - de Boer, Carl G.

AU - Jenkins, Russell W.

AU - Lieb, David J.

AU - Chen, Jonathan H.

AU - Frederick, Dennie T.

AU - Barzily-Rokni, Michal

AU - Freeman, Samuel S.

AU - Reuben, Alexandre

AU - Hoover, Paul J.

AU - Villani, Alexandra Chloé

AU - Ivanova, Elena

AU - Portell, Andrew

AU - Lizotte, Patrick H.

AU - Aref, Amir R.

AU - Eliane, Jean Pierre

AU - Hammond, Marc R.

AU - Vitzthum, Hans

AU - Blackmon, Shauna M.

AU - Li, Bo

AU - Gopalakrishnan, Vancheswaran

AU - Reddy, Sangeetha M.

AU - Cooper, Zachary A.

AU - Paweletz, Cloud P.

AU - Barbie, David A.

AU - Stemmer-Rachamimov, Anat

AU - Flaherty, Keith T.

AU - Wargo, Jennifer A.

AU - Boland, Genevieve M.

AU - Sullivan, Ryan J.

AU - Getz, Gad

AU - Hacohen, Nir

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors. Two distinct states of CD8+ T cells were defined by clustering and associated with patient tumor regression or progression. A single transcription factor, TCF7, was visualized within CD8+ T cells in fixed tumor samples and predicted positive clinical outcome in an independent cohort of checkpoint-treated patients. We delineated the epigenetic landscape and clonality of these T cell states and demonstrated enhanced antitumor immunity by targeting novel combinations of factors in exhausted cells. Our study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy. Single-cell analysis of immune cells from melanoma patients treated with immune checkpoint therapy uncovers a TCF7+ memory-like state in the cytotoxic T cell population and demonstrates its association with a positive outcome.

AB - Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors. Two distinct states of CD8+ T cells were defined by clustering and associated with patient tumor regression or progression. A single transcription factor, TCF7, was visualized within CD8+ T cells in fixed tumor samples and predicted positive clinical outcome in an independent cohort of checkpoint-treated patients. We delineated the epigenetic landscape and clonality of these T cell states and demonstrated enhanced antitumor immunity by targeting novel combinations of factors in exhausted cells. Our study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy. Single-cell analysis of immune cells from melanoma patients treated with immune checkpoint therapy uncovers a TCF7+ memory-like state in the cytotoxic T cell population and demonstrates its association with a positive outcome.

KW - cancer immunotherapy

KW - CD8 T cells

KW - checkpoint blockade

KW - single-cell RNA-seq

KW - TCF7

UR - http://www.scopus.com/inward/record.url?scp=85055560004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055560004&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2018.10.038

DO - 10.1016/j.cell.2018.10.038

M3 - Article

C2 - 30388456

AN - SCOPUS:85055560004

VL - 175

SP - 998-1013.e20

JO - Cell

JF - Cell

SN - 0092-8674

IS - 4

ER -